SalioGen Therapeutics
Burlington
About SalioGen Therapeutics
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $135.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2022)
- Website: saliogen.com
- Phone: (650) 906-9468
Industries & Categories
Biotechnology, Genetics, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/saliogen-therapeutics-107421 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.